MorphoSys AG Cost of Revenue 2011-2026 | MOR

Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.

What is included in the cost of revenue

Cost Category	Examples
Production Costs	Materials, wages of production staff, depreciation of equipment
Service and Support	Customer service, user support, technical assistance
Delivery and Logistics	Packaging, delivery of goods to customers
Hosting and Infrastructure	Servers, cloud platforms (especially for IT and SaaS companies)
Content and Licenses	License purchases, production royalties (e.g., in streaming services)

Importance of the Metric

Helps to understand how costly the revenue-generating process is.
A high cost of revenue may indicate:
Poor cost control
Low operational efficiency
A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.

Annual Cost of Revenue MorphoSys AG

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	32.2 M	9.17 M	12.1 M	1.8 M	-	-	-	-	-	-	-

All numbers in EUR currency

Indicator range from annual reports

Maximum	Minimum	Average
32.2 M	1.8 M	13.8 M

Cost of Revenue of other stocks in the Biotechnology industry

Issuer	Cost of Revenue	Price	% 24h	Market Cap	Country
Xeris Pharmaceuticals XERS	42.6 M	$ 6.03	-1.55 %	$ 885 M	USA
I-Mab IMAB	27.2 M	-	-	$ 866 M	China
UroGen Pharma Ltd. URGN	12.4 M	$ 19.2	-11.52 %	$ 554 M	Israel
uniQure N.V. QURE	1.69 M	$ 10.89	-30.36 %	$ 530 M	Niderland
GT Biopharma GTBP	57 K	$ 0.47	-2.41 %	$ 892 K	USA
Midatech Pharma plc MTP	926 K	-	-18.52 %	$ 27.3 M	Britain
Adverum Biotechnologies ADVM	100 K	-	-	$ 86.2 M	USA
Acorda Therapeutics ACOR	15.3 M	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	76 K	-	4.01 %	$ 150 M	Canada
CureVac N.V. CVAC	238 M	-	-	$ 867 M	Germany
Aeterna Zentaris AEZS	90 K	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	40 K	-	-10.17 %	$ 12.2 K	USA
AIkido Pharma AIKI	9 K	-	1.93 %	$ 17.4 M	USA
Agenus AGEN	3.11 M	$ 3.36	0.86 %	$ 1.2 M	USA
Ayala Pharmaceuticals AYLA	602 K	-	-	$ 7.46 M	Israel
Agios Pharmaceuticals AGIO	6.34 M	$ 29.16	-3.54 %	$ 1.69 B	USA
Advaxis ADXS	13 K	-	-9.65 %	$ 45.9 M	USA
Albireo Pharma ALBO	1.36 M	-	-0.23 %	$ 916 M	USA
Alector ALEC	51.8 M	$ 2.19	-9.77 %	$ 226 M	USA
Entera Bio Ltd. ENTX	209 K	$ 1.38	-0.72 %	$ 63.3 M	Israel
Evogene Ltd. EVGN	767 K	$ 0.84	-4.24 %	$ 27.9 M	Israel
Ampio Pharmaceuticals AMPE	369 K	-	-11.43 %	$ 502 K	USA
Amarin Corporation plc AMRN	96 M	$ 13.98	1.27 %	$ 5.7 B	Irlanda
AbbVie ABBV	18.2 B	$ 233.57	0.64 %	$ 413 B	USA
Blueprint Medicines Corporation BPMC	20.2 M	-	-	$ 8.14 B	USA
AIM ImmunoTech AIM	1.25 M	$ 0.8	-11.6 %	$ 38.5 M	USA
Aptorum Group Limited APM	421 K	$ 0.83	5.37 %	$ 4.53 M	China